Zobrazeno 1 - 5
of 5
pro vyhledávání: '"329"'
Autor:
U. Creutzig, P. Smisek, L. Hovi, B. Stark, B. Gibson, B. Razzouk, Carmelo Rizzari, R. Tamminga, G.J.L. Kaspers, A. Baruchel, S. Ha, D. Reinhardt, Y. Bertrand, M. Zimmermann, H. Armendariz, Alexei Maschan, M. Dworzak, O. Smith
Publikováno v:
Blood. 112:2977-2977
Relapse remains the commonest adverse event in newly diagnosed AML patients, and the reported long-term survival after relapse in pediatric AML is 20–30%. Allogeneic stem cell transplantation (allo-SCT) in CR1 is employed by several groups with the
Publikováno v:
Blood. 110:1310-1310
Syk kinase is central to FcR and B-cell signaling in inflammatory cells. By inhibiting syk, and thereby IgG signaling, R788 (a small molecule prodrug for biologically active R406), inhibits the downstream activation of mast cells, macrophages and B-c
Autor:
Yasuo Morishima, Mina Nishimori, Shunichi Fukuhara, Yuichi Akiyama, Keiko Hoshi, Yoshitsugu Yamada, Yoshihisa Kodera, Yasutaka Hoshi, Masahiro Tsuchida
Publikováno v:
Blood. 99:1995-2001
To promote bone marrow donation, both the safety and well-being of healthy unrelated volunteer donors must be protected. This prospective cohort study evaluated donors' health-related quality of life (HRQOL) and identified factors associated with it.
Autor:
Ursula Haak, Rita Pasold, Sabine Hahnfels, Thomas-Hein Ittel, Christian Klinkenstein, Sabine Neser, Andreas Neubauer, Franz-Adolph Hoffmann, Ullrich von Gruenhagen, Ullrich Mey, Klaus Dachselt, Dorothee Bleyl, Mathias Freund, Ralph Naumann, Klaus Hieke, Heiner Wolf, Erika Kettner, Thomas Fietz, Volker Lakner, Helga Schwenke, Gottfried Doelken, Detlev Haehling, Henning Eschenburg, Klaus Hoeffken, Michael Assmann, Dietger Niederwieser, Michael Herold, Astrid Franke, Norbert Grobe, Robert Rohrberg, Michael R. Clemens, H.-H. Wolf, Peter Richter
Publikováno v:
Blood. 104:87-87
Background: Clinical superiority of R-MCP (rituximab, mitoxantrone, chlorambucil, prednisolone) vs. MCP alone in patients with advanced stage indolent Non-Hodgkin’s-Lymphoma was demonstrated in a prospective, randomized, controlled, multicenter cli
Publikováno v:
Blood. 104:4939-4939
Background: Zoledronic acid is a new-generation bisphosphonate with demonstrated efficacy and safety in the treatment of bone lesions in patients with multiple myeloma and solid tumors using a monthly regimen of 4 mg infused over 15 minutes. This pha